Literature DB >> 17927648

Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus.

Hedvig Varga1, Arpad Pardutz, Eniko Vamos, Imola Plangar, Eszter Egyud, Janos Tajti, Ferenc Bari, Laszlo Vecsei.   

Abstract

OBJECTIVE: The aim of the present study was to determine which isoform of the cyclooxygenase (COX) enzyme plays a role in the neuronal nitric oxide synthase (nNOS) activation caused by nitroglycerin (NTG), in the most caudal part of the trigeminal caudal nucleus (TNC) of the rat.
BACKGROUND: Nitric oxide donor, NTG, can trigger migraine attack in migraineurs, but not in healthy persons. In rats, subcutaneous administration of NTG (10 mg/kg) increases significantly the number of nNOS-immunoreactive neurons in the TNC after 4 hours, which could be attenuated by acetyl-salicylate (Aspirin), a nonselective COX-inhibitor.
METHODS: SPRD rats were divided into 3 groups: (1) control group (no drug administration), (2) NS398 (selective COX-2 inhibitor) administration (1, 3, or 5 mg/kg), and (3) SC560 (selective COX-1 inhibitor) administration (1, 5, or 10 mg/kg). Thirty minutes after drug administration, the animals received NTG (10 mg/kg) or placebo injection. Four hours later the animals were transcardially perfused and the cervical part of the TNC was removed for immunohistochemistry. Results.-The selective COX-2 inhibitor NS398 in contrast to the selective COX-1 inhibitor SC560 attenuates the NTG-induced nNOS expression dose-dependently.
CONCLUSION: These findings suggest that metabolites deriving from COX-2 (but not COX-1) may be the most important factors in the NTG-induced nNOS expression. These data could help to better understand the pathogenesis of headaches and the action of antimigraine drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17927648     DOI: 10.1111/j.1526-4610.2006.00721.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

1.  A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches.

Authors:  Oliver Summ; Anna P Andreou; Simon Akerman; Peter J Goadsby
Journal:  J Headache Pain       Date:  2010-10-27       Impact factor: 7.277

Review 2.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

3.  Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine.

Authors:  Xiaomeng Dong; Yaozhi Hu; Long Jing; Jinbo Chen
Journal:  Mol Med Rep       Date:  2015-04-15       Impact factor: 2.952

Review 4.  NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data.

Authors:  Arpad Pardutz; Jean Schoenen
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-17

5.  Differential actions of indomethacin: clinical relevance in headache.

Authors:  Oliver Summ; Anna P Andreou; Simon Akerman; Philip R Holland; Jan Hoffmann; Peter J Goadsby
Journal:  Pain       Date:  2021-02-01       Impact factor: 7.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.